Drug Profile

Laduviglusib - Korro Bio

Alternative Names: CHIR-99021; CHR00921; CT-99021; FX03; GTPL8014

Latest Information Update: 11 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Frequency Therapeutics
Developer Korro Bio
Class Small molecules
Mechanism of Action Glycogen synthase kinase 3 alpha inhibitors; Glycogen synthase kinase 3 beta inhibitors; Wnt signalling pathway stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Aug 2023 Interim pharmacodynamics data from a preclinical studies presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-2023)
13 Feb 2023 Discontinued - Preclinical for Fetal growth retardation in USA (unspecified route)
13 Feb 2023 Discontinued - Preclinical for Sensorineural hearing loss in USA (Intratympanic)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com